Efficiency of treatment by acenocoumarol in patients with permanent form of atrial fibrillation, with using models of personalized medicine

Cover Page

Cite item

Full Text

Abstract

Acenocoumarol is the global standard of anticoagulant therapy, but often treatment with acenocoumarol accompanied by adverse drug reactions. Model of personalized medicine, actively developing now, can reduce the number of side effects during therapy of Acenocoumarol, mainly due to individual genetic characteristics (polymorphisms of genes CYP2C9 and VKORC1). This will help to reduce side effects of therapy and reduce treatment costs.

About the authors

I V Kukes

The Sechenov Moscow Medical Academy

Email: somvoz@live.ru <mailto:somvoz@live.ru>
Кафедра клинической фармакологиии пропедевтики внутренних болезнейЛечебный факультет, ГКБ23; Московская медицинская академия имени И.М. Сеченова; The Sechenov Moscow Medical Academy

V N Shan

Moscow State University

Email: somvoz@live.ru
Кафедра финансовой стратегииФакультет московской школы экономики; Московский государственный университет имени М.В. Ломоносова; Moscow State University

References


Copyright (c) 2009 Кукес И.В., Шан В.Н.

Creative Commons License
This work is licensed under a Creative Commons Attribution 4.0 International License.

This website uses cookies

You consent to our cookies if you continue to use our website.

About Cookies